

**Supplementary Table 2.** Voting results for questions about the treatment strategies after transarterial chemoembolization (TACE) that the participants considered in the following situations

Question	Answer	No. to Yes	High-volume centers (n=42)			Centers in metropolitan (n=120)		
			Yes	No	P-value	Yes	No	P-value
Q11	Sorafenib	137 (85.1)	39 (92.9)	98 (82.4)	0.132	100 (83.3)	37 (90.2)	0.446
	HAIC	62 (38.5)	12 (28.6)	50 (42.0)	0.124	47 (39.2)	15 (36.6)	0.769
	Repeat TACE	37 (23.0)	11 (26.2)	26 (21.8)	0.565	28 (23.3)	9 (22.0)	1.000
	Beads TACE	8 (5.0)	1 (2.4)	7 (5.9)	0.682	5 (4.2)	3 (7.3)	0.421
	Radiotherapy	114 (70.8)	33 (78.6)	81 (68.1)	0.239	88 (73.3)	26 (63.4)	0.228
	Other systemic CTx	29 (18.0)	9 (21.4)	20 (16.8)	0.492	26 (21.7)	3 (7.3)	0.057
Q12	Sorafenib	97 (60.2)	28 (66.7)	69 (58.0)	0.323	71 (59.2)	26 (63.4)	0.631
	HAIC	41 (25.5)	9 (21.4)	32 (26.9)	0.542	35 (29.2)	6 (14.6)	0.095
	Repeat TACE	111 (68.9)	30 (71.4)	81 (68.1)	0.686	84 (70.0)	27 (65.9)	0.620
	Beads TACE	14 (8.7)	3 (7.1)	11 (9.2)	1.000	12 (10.0)	2 (4.9)	0.521
	Radiotherapy	38 (23.6)	8 (19.0)	30 (25.2)	0.528	26 (21.7)	12 (29.3)	0.322
	Other systemic CTx	13 (8.1)	5 (11.9)	8 (6.7)	0.326	11 (9.2)	2 (4.9)	0.518
	Hospice care	4 (2.5)	4 (3.3)	0 (0.0)	0.573	2 (4.8)	2 (1.7)	0.279
Q13	Sorafenib	93 (57.8)	69 (57.5)	24 (58.5)	0.908	24 (57.1)	69 (58.0)	0.924
	HAIC	50 (31.1)	12 (28.6)	38 (31.9)	0.686	41 (34.2)	9 (22.0)	0.173
	Repeat TACE	75 (46.6)	14 (33.3)	61 (51.3)	0.045	54 (45.0)	21 (51.2)	0.491
	Beads TACE	4 (2.5)	3 (7.1)	1 (0.8)	0.055	4 (3.3)	0 (0.0)	0.573
	Radiotherapy	127 (78.9)	39 (92.9)	88 (73.9)	0.008	97 (80.8)	30 (73.2)	0.299
	Other systemic CTx	8 (5.0)	2 (4.8)	6 (5.0)	1.000	4 (3.3)	4 (9.8)	0.115
Q14	Sorafenib	106 (65.8)	27 (64.3)	79 (66.4)	0.805	77 (64.2)	29 (70.7)	0.444
	HAIC	58 (36.0)	15 (35.7)	43 (36.1)	0.961	48 (4.0)	10 (24.4)	0.072
	Repeat TACE	53 (32.9)	15 (35.7)	38 (31.9)	0.654	12 (29.3)	41 (34.2)	0.564
	Beads TACE	4 (2.5)	2 (4.8)	2 (1.7)	0.279	4 (3.3)	0 (0.0)	0.573
	Radiotherapy	138 (85.7)	41 (97.6)	97 (81.5)	0.009	107 (89.2)	31 (75.6)	0.032
	Other systemic CTx	9 (5.6)	4 (9.5)	5 (4.2)	0.241	4 (9.8)	5 (4.2)	0.234
	Hospice care	3 (1.9)	0 (0.0)	3 (2.5)	0.568	2 (1.7)	1 (2.4)	1.000
Q15	Sorafenib	153 (95.0)	40 (95.2)	113 (95.0)	1.000	115 (95.8)	38 (92.7)	0.421
	HAIC	9 (5.6)	3 (7.1)	6 (5.0)	0.698	7 (5.8)	2 (4.9)	1.000
	Repeat TACE	48 (29.8)	14 (33.3)	34 (28.6)	0.562	35 (29.2)	13 (31.7)	0.759
	Beads TACE	2 (1.2)	0 (0.0)	2 (1.7)	1.000	1 (0.8)	1 (2.4)	0.446
	Radiotherapy	59 (36.6)	21 (50.0)	38 (31.9)	0.037	46 (38.3)	13 (31.7)	0.447
	Other systemic CTx	31 (19.3)	7 (16.7)	24 (20.2)	0.820	26 (21.7)	5 (12.2)	0.252
	Hospice care	4 (2.5)	1 (2.4)	3 (2.5)	1.000	3 (2.5)	1 (2.4)	1.000
Q16	Sorafenib	65 (40.4)	21 (50.0)	44 (37.0)	0.139	49 (40.8)	16 (39.0)	0.839
	HAIC	19 (11.8)	6 (14.3)	13 (10.9)	0.583	16 (13.3)	3 (7.3)	0.406
	Repeat TACE	29 (18.0)	9 (21.4)	20 (16.8)	0.492	23 (19.2)	6 (14.6)	0.641
	Beads TACE	2 (1.2)	0 (0.0)	2 (1.7)	1.000	0 (0.0)	2 (4.9)	0.064
	Radiotherapy	61 (37.9)	17 (40.5)	44 (37.0)	0.688	45 (37.5)	16 (39.0)	0.862
	Other systemic CTx	51 (31.7)	12 (28.6)	39 (32.8)	0.615	41 (34.2)	10 (24.4)	0.245
	Hospice care	74 (46.0)	16 (38.1)	58 (48.7)	0.234	53 (44.2)	21 (51.2)	0.434

**Supplementary Table 2.** Continued

Question	Answer	No. to Yes	High-volume centers (n=42)			Centers in metropolitan (n=120)		
			Yes	No	P-value	Yes	No	P-value
Q17	Sorafenib	94 (58.4)	27 (64.3)	67 (56.3)	0.367	65 (54.2)	29 (70.7)	0.063
	HAIC	39 (24.2)	9 (21.4)	30 (25.2)	0.681	32 (26.7)	7 (17.1)	0.292
	Repeat TACE	75 (46.6)	16 (38.1)	59 (49.6)	0.200	56 (46.7)	19 (46.3)	0.971
	Beads TACE	11 (6.8)	2 (4.8)	9 (7.6)	0.730	10 (8.3)	1 (2.4)	0.292
	Radiotherapy	113 (70.2)	36 (85.7)	77 (64.7)	0.011	90 (75.0)	23 (56.1)	0.022
	Other systemic CTx	14 (8.7)	3 (7.1)	11 (9.2)	1.000	12 (10.0)	2 (4.9)	0.521
	Hospice care	5 (3.1)	0 (0.0)	5 (4.2)	0.328	3 (2.5)	2 (4.9)	0.602

Values are presented as n (%) unless otherwise indicated. 'Q11' is 'suspicious TACE failure or refractoriness'. 'Q12' is 'multiple local recurrences with Child-Pugh class A'. 'Q13' is 'Vp3/4 portal vein thrombosis'. 'Q14' is 'main portal vein invasion'. 'Q15' is 'extrahepatic metastasis with Child-Pugh class A'. 'Q16' is 'extrahepatic metastasis with Child-Pugh class B'. 'Q17' is 'insufficient necrosis after at least two treatments of TACE with Child-Pugh class A'. P-value was calculated using chi-square test and Fisher's exact test.

HAIC, hepatic arterial infusion chemotherapy; CTx, chemotherapy.